Horizaon Discovery -- Horizon Discovery (Horizon) today announced it has entered into a four-year strategic collaboration with Novartis. This is the second business agreement between the companies and sees the use of Horizon’s proprietary GENESISTM gene-engineering platform to develop a broad panel of custom generated genetically-defined human ‘X-MAN’ cancer models for deployment in Novartis’s drug discovery research programs.
